Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takashi Seto

Showing results (201-210 of 242) with videos related to

Pageof 25
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2009
Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203)Koji Takeda, Toyoaki Hida, Tosiya Sato, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 12, 2013
Histology and smoking status predict survival of patients with advanced non-small-cell lung cancer. Results of West Japan Oncology Group (WJOG) Study 3906LYoshihito Kogure, Masahiko Ando, Hideo Saka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2023
Five-Year Overall Survival Analysis of the JIPANG Study: Pemetrexed or Vinorelbine Plus Cisplatin for Resected Stage II-IIIA Nonsquamous Non-Small-Cell Lung CancerHirotsugu Kenmotsu, Nobuyuki Yamamoto, Toshihiro Misumi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2010
Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105Nobuyuki Yamamoto, Kazuhiko Nakagawa, Yasumasa Nishimura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 15, 2020
Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung CancerHirotsugu Kenmotsu, Nobuyuki Yamamoto, Takeharu Yamanaka, et al.
Cancer|February 2, 2016
Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trialMasayuki Takeda, Takeharu Yamanaka, Takashi Seto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2018
Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung CancerYi-Long Wu, James Chih-Hsin Yang, Dong-Wan Kim, et al.
Frontiers in Oncology|January 26, 2023
Comprehensive biomarker analysis from phase II study of nivolumab in patients with thymic carcinomaYuki Katsuya, Shigehisa Kitano, Makiko Yamashita, et al.
Journal for Immunotherapy of Cancer|February 2, 2022
Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)Takashi Seto, Kaname Nosaki, Mototsugu Shimokawa, et al.
The Lancet. Oncology|December 22, 2009
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialTetsuya Mitsudomi, Satoshi Morita, Yasushi Yatabe, et al.
Pageof 25

Showing results (201-210 of 242) with videos related to

Sort By:
Pageof 25
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2009
Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203)Koji Takeda, Toyoaki Hida, Tosiya Sato, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 12, 2013
Histology and smoking status predict survival of patients with advanced non-small-cell lung cancer. Results of West Japan Oncology Group (WJOG) Study 3906LYoshihito Kogure, Masahiko Ando, Hideo Saka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2023
Five-Year Overall Survival Analysis of the JIPANG Study: Pemetrexed or Vinorelbine Plus Cisplatin for Resected Stage II-IIIA Nonsquamous Non-Small-Cell Lung CancerHirotsugu Kenmotsu, Nobuyuki Yamamoto, Toshihiro Misumi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2010
Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105Nobuyuki Yamamoto, Kazuhiko Nakagawa, Yasumasa Nishimura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 15, 2020
Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung CancerHirotsugu Kenmotsu, Nobuyuki Yamamoto, Takeharu Yamanaka, et al.
Cancer|February 2, 2016
Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trialMasayuki Takeda, Takeharu Yamanaka, Takashi Seto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2018
Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung CancerYi-Long Wu, James Chih-Hsin Yang, Dong-Wan Kim, et al.
Frontiers in Oncology|January 26, 2023
Comprehensive biomarker analysis from phase II study of nivolumab in patients with thymic carcinomaYuki Katsuya, Shigehisa Kitano, Makiko Yamashita, et al.
Journal for Immunotherapy of Cancer|February 2, 2022
Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)Takashi Seto, Kaname Nosaki, Mototsugu Shimokawa, et al.
The Lancet. Oncology|December 22, 2009
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialTetsuya Mitsudomi, Satoshi Morita, Yasushi Yatabe, et al.
Pageof 25